Last reviewed · How we verify
Placebo, extended-release microspheres — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo, extended-release microspheres (Placebo, extended-release microspheres) — Luye Pharma Group Ltd.. This drug is a placebo, meaning it has no active therapeutic effect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo, extended-release microspheres TARGET | Placebo, extended-release microspheres | Luye Pharma Group Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo, extended-release microspheres CI watch — RSS
- Placebo, extended-release microspheres CI watch — Atom
- Placebo, extended-release microspheres CI watch — JSON
- Placebo, extended-release microspheres alone — RSS
Cite this brief
Drug Landscape (2026). Placebo, extended-release microspheres — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-extended-release-microspheres. Accessed 2026-06-09.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing